Visterra, a focused on creating vaccines for infectious diseases prone to mutation and resistance, filed on Tuesday with the SEC to raise up to $69 million in an initial public offering.
The Cambridge, MA-based company, which was founded in 2007 and booked n/a in sales for the 12 months ended September 30, 2015, plans to list on the Nasdaq under the symbol VIST. Visterra filed confidentially on n/a. Leerink Partners and Stifel are the joint bookrunners on the deal. No pricing terms were disclosed.
